^
    4ms
    LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov)
    P1/2; Active, not recruiting --> Completed
    Trial completion
    |
    OncoPanel™ Assay
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib) • LY3022855
    10ms
    Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P1, N=12, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    Keytruda (pembrolizumab) • cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • LY3022855
    1year
    A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=72, Completed, Eli Lilly and Company | N=178 --> 72
    Enrollment change • Combination therapy • Metastases
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • LY3022855
    1year
    A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma. (PubMed, Invest New Drugs)
    CSF1R inhibition with LY3022855 in combination with BRAF/MEK inhibition with vemurafenib and cobimetinib was difficult to tolerate in a small melanoma population. One response was observed in this small sample of patients suggesting this combination might be worthy of further exploration.
    P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal • IO biomarker
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib) • LY3022855
    over2years
    LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov)
    P1/2; Trial primary completion date: Jun 2022 --> Dec 2022
    Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    OncoPanel™ Assay
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib) • LY3022855
    over3years
    A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. (PubMed, Invest New Drugs)
    The RP2D was LY3022855 100 mg QW with durvalumab 750 mg Q2W. ClinicalTrials.gov ID: NCT02718911 (Registration Date: May 3, 2011).
    Clinical • P1 data • Journal • Combination therapy
    |
    CSF1R (Colony stimulating factor 1 receptor)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • LY3022855
    over3years
    LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. (PubMed, Invest New Drugs)
    Conclusions LY3022855 was well tolerated and showed dose-dependent pharmacokinetics-pharmacodynamics and limited clinical activity in a heterogenous solid tumor population. ClinicalTrials.gov ID NCT01346358 (Registration Date: May 3, 2011).
    Journal
    |
    CSF1R (Colony stimulating factor 1 receptor)
    |
    LY3022855